SEC Filings

Filing links are provided when reliable SEC filing data is available.

Recent Filings

Form	Filing Date	Accepted	Document
4	Sep 3, 2026	Sep 3, 2026	View filing
144	Sep 2, 2026	Sep 2, 2026	View filing
144	Sep 1, 2026	Sep 1, 2026	View filing
8-K	Aug 26, 2026	Aug 25, 2026	View filing
10-Q	Aug 6, 2026	Aug 6, 2026	View filing
8-K	Aug 6, 2026	Aug 6, 2026	View filing
SC 13G	May 15, 2026	May 15, 2026	View filing
SC 13G	May 15, 2026	May 15, 2026	View filing
10-Q	May 7, 2026	May 7, 2026	View filing
8-K	May 7, 2026	May 7, 2026	View filing
3	Mar 12, 2026	Mar 12, 2026	View filing
4	Mar 6, 2026	Mar 6, 2026	View filing
4	Mar 2, 2026	Mar 2, 2026	View filing
4	Mar 2, 2026	Mar 2, 2026	View filing
4	Mar 2, 2026	Mar 2, 2026	View filing
4	Mar 2, 2026	Mar 2, 2026	View filing
4	Mar 2, 2026	Mar 2, 2026	View filing
4	Mar 2, 2026	Mar 2, 2026	View filing
4	Mar 2, 2026	Mar 2, 2026	View filing
4	Mar 2, 2026	Mar 2, 2026	View filing
4	Mar 2, 2026	Mar 2, 2026	View filing
4	Mar 2, 2026	Mar 2, 2026	View filing
4	Mar 2, 2026	Mar 2, 2026	View filing
4	Mar 2, 2026	Mar 2, 2026	View filing
4	Mar 2, 2026	Mar 2, 2026	View filing
4	Mar 2, 2026	Mar 2, 2026	View filing
4	Mar 2, 2026	Mar 2, 2026	View filing
8-K	Mar 2, 2026	Mar 2, 2026	View filing
S-8	Feb 27, 2026	Feb 27, 2026	View filing
424B4	Feb 27, 2026	Feb 27, 2026	View filing

About Generate Biomedicines, Inc.

Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.

Somerville, MA

312 employees

generatebiomedicines.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Michael T. Nally

View full financials